Patients
Decompensated cirrhosis, DILI, decompensated hepatitis B cirrhosis, PBC, hepatitis A, hereditary metabolic liver disease, primary biliary cholangitis, PSC, Infection, AIH
VIRUS, DECOMPENSATED CIRRHOSIS, ALCOHOLIC LIVER DISEASE, PBC, PRIMARY BILIARY CHOLANGITIS, DRUG-INDUCED LIVER INJURY, HEPATITIS A, HEPATOCELLULAR CARCINOMA, PRIMARY SCLEROSING CHOLANGITIS, INFECTION
This was a single-center, retrospective study. This study recruited patients with decompensated hepatitis B cirrhosis who were hospitalized in Zhejiang Provincial People’s Hospital (Hangzhou, China) between July 2018 and June 2021. Inclusion criteria: (1) patients with Decompensated cirrhosis with or without HRS according to the diagnostic criteria; (2) 18–90 years of age; and (3) Compliance with HRS diagnostic criteria. Exclusion criteria: (1) Patients infected with hepatitis A, C, D, or E virus; (2) Infection with human immunodeficiency virus (HIV); (3) Non-HBV with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), hereditary metabolic liver disease, drug-induced liver injury (DILI) or alcoholic liver disease; (5) Hepatocellular carcinoma; or (6) Incomplete clinical data. The study was approved by the Ethics Committee of Zhejiang Provincial People’s Hospital and conformed to the ethical guidelines of the Helsinki Declaration. Researchers only analyzed anonymous data, so they gave up informed consent.